Thus, tools to either block or activate the AT2 receptor (Figure 1) are under development but preclinical studies are still needed to elucidate AT2 functions in cancer and to adequately target this receptor, in particular in breast cancer. The gene discussed is AGTR2; the disease is breast cancer.